1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow inavolisib: new trials by email Literature Review of inavolisib trials Research Report on inavolisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer Capecitabine, Talazoparib, Pembrolizumab - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Terminated | Bryan Schneider, MD | 52 | 2021-08-24 | 2025-05-31 |
Breast Neoplasms (1) · Triple Negative Breast Neoplasms (1)
United States (1)